HC Wainwright & Co. Reiterates Buy on Atossa Therapeutics, Maintains $6 Price Target
Atossa Genetics Inc. +2.11% Pre
Atossa Genetics Inc. ATOS | 1.45 1.45 | +2.11% 0.00% Pre |
HC Wainwright & Co. analyst Emily Bodnar reiterates Atossa Therapeutics (NASDAQ:
ATOS) with a Buy and maintains $6 price target.